Transcript - Chapter 9 of 10 - The Patents
1:30:18 - 1:39:07 - Interactive sourced transcript
ON SCREEN TITLE CARD:
The United States Government
Stanislaw Burzynski, MD, PhD and all past, present, and future cancer patients.
Most of us would assume, that with any story such as this, surely there’s another side to it. Our story is no exception.
After the National Cancer Institute intentionally violated all protocols of their own Antineoplaston trials, and after all state and federal agencies had failed in their 14-year campaign to remove Burzynski from society—after all of the dust settled—a profound truth began to emerge.
NARRATOR (reading from highlighted sections of an internal NCI memo, 10/31/91):
It was October 4th, 1991, that America’s National Cancer Institute hosted their site visit to Burzynski’s clinic, and verified for themselves that “anti-tumor activity was documented by the use of Antineoplastons.”
[SOURCE: 11/15/91 Letter and 10/30/91 Review of Brain Cancers Treated by Burzynski by the NCI]
NARRATOR (reading from highlighted sections of US Patent #6,037,376):
Seventeen days later, on October 21st, 1991, The United States of America as represented by "The Department of Health and Human Services", and "Dr. Dvorit Samid" filed a patent for Antineoplastons AS2-1. They even had the audacity to include Burzynski as a reference. “The invention described herein may be manufactured, used and licensed by or for the government, for governmental purposes...” [SOURCE: Patent #6,037,376 pg 1, 6 of PDF]
At the time, Burzynski had no idea this had happened, but did have his suspicions when they began to openly test Phenylacetate without him, and the National Cancer Institute knew it.
NARRATOR (reading from highlighted sections of internal leaked NCI memo 4/29/93):
In an April 1993 NCI memo, distributed to those involved with Burzynski, they state their concerns: Political issues are a real concern. Congressman Bedell is concerned we are taking the Antineoplastons away from Burzynski. Burzynski has patents on Antineoplastons. Since phenylacetic acid, or Phenylacetate, may be the active component of Antineoplastons, our involvement has become an issue.
[SOURCE: NCI Internal memo 4/29/93 pg 2]
NARRATOR (reading from highlighted sections of US Patent #5,635,532):
Five months later, the United States of America and Dr. Dvorit Samid file their second extended patent on Antineoplastons. And, guess who else was in it? [Elan Pharmaceutical Corporation].
[SOURCE: Patent #5,635,532 pg 1, 34 of PDF]
NARRATOR (reading from highlighted sections of numerous USA DHHS Patents on Antineoplastons):
In March of the following year, America files it’s most extensive updated Antineoplaston patent to date, spanning one hundred and eleven pages. [SOURCE: Patent #5,605,930]
Seven months later, they file a fourth one. [SOURCE: Patent #5,852,056]
June 6, 1995, the United States government has a field day filing their fifth [US Patent #5,654,333], sixth [US Patent #5661179], seventh [US Patent #5,635,533], and eighth [US Patent #5,710,178] extended patent on Antineoplastons. The following day, America files it’s ninth [US Patent #5,843,994], tenth [US Patent #5,877,213], and eleventh [US Patent #5,881,124] extended Antineoplaston patent.
And, a couple of months after the eleventh patent was filed, Dr. Michael Friedman leaves his position at the National Cancer Institute, and becomes Deputy Commissioner of Operations for the Food and Drug Administration, working directly under Dr. David Kessler. [SOURCE: FDA Deputy Commissioners]
And by November of that year, after a decade of failed grand juries, the United States of America’s Food and Drug Administration finally manages to indict Dr. Burzynski. [SOURCES]
One month into America’s criminal trial against Burzynski, America’s first patent on Antineoplaston AS2-1 is approved. A month after America fails in their second trial against Burzynski, their second and third Antineoplaston patents are approved. Over the course of the next three years, the United States patent office approves all eleven copy-cat patents on Antineoplastons AS2-1. [SOURCE: The patents sourced above show their "approval date" and "filing date"]
STANISLAW BURZYNSKI - on camera interview:
And as we know, all of this was being done based on the fact that the United States, which is the National Institutes of Health, together with a pharmaceutical company, which is Elan Pharmaceuticals, was trying simply to steal my invention. That’s what they wanted. It’s not that we had a successful visit from the National Cancer Institute in which they determined that “this treatment works great” and they decided that we should go into Phase 2 clinical trials which would be sponsored by them. No. This gave the idea of some high-ups at the FDA to conspire with the pharmaceutical company so that they could steal the invention from me and get it, because it was good.
That’s the whole story.
They knew that if I’d be still free, they won’t be able to do it. Because they knew that if I would sue them they wouldn’t have a chance in court because we have our patents before them. So that’s why they attempted to wipe me out financially, to put me in prison, to attack me from every possible angle: FDA, which is the federal government, state government... to be able to steal my invention. That’s the real thing from the National Cancer Institute and Elan Pharmaceuticals. They failed. We survived, and we continue to move forward.
NARRATOR (reading from highlighted sections of US Patent #5,605,930):
These patents are full of useful information. Aside from noticing their blatant infringement, “Compositions and Methods for Treating and Preventing Cancer” [Pg 1], using the distribution of Antineoplastons AS2-1’s ingredients. [pg 71] They enthusiastically state: “The neoplastic conditions treatable by this method include neuroblastoma, leukemia, myelodisplasia, acute glioma, prostate cancer, breast cancer, melanoma, lung cancer, medulloblastoma, and lymphoma” to name a few. [pg 49] They also point out how Antineoplastons can also be used as a cancer preventative. [pg 56]
[SOURCE: US Patent #5,605,930 pg 1, 49, 56, 71]
However, the most revealing piece of information found in these patents is where they state: “Current approaches to combat cancer rely primarily on the use of chemicals and radiation, which are themselves carcinogenic and may promote recurrences and the development of metastatic disease.” Let’s read that one again, shall we? “Current approaches to combat cancer rely primarily on the use of chemicals and radiation, which are themselves carcinogenic and may promote recurrences and the development of metastatic disease.” [SOURCE: US Patent #5,605,930 pg 56]
Dr. JULIAN WHITAKER - on camera interview:
Now how could the U.S. Patent Office be corrupted to the point that they issue patents on medical therapies that have already been patented, and issue them to someone who had nothing to do with their discovery or use? How could that happen? And how could the patent office then assign these fraudulent patents to some of the most powerful institutions in American government? And imagine, all of this was being done while these same government agencies were spending millions of taxpayers dollars trying to put Dr. Burzynski in jail so he could not fight the criminal theft of his discovery. Well, what about the ten million patients who have died of cancer over the last twenty years? The majority of them could have been saved if the government had not blocked the therapy that they new could save them.